Cingulate Inc. (CING) - Q1 2026 10-Q Summary
Business Context and Reporting Period
Cingulate Inc. is a biopharmaceutical company developing once-daily, multi-dose tablet therapies for ADHD and anxiety using its Precision Timed Release (PTR) platform. The reporting period covers the three months ended March 31, 2026. The Company is a pre-revenue entity with no approved products. Its lead asset, CTx-1301 (dexmethylphenidate) for ADHD, has a New Drug Application (NDA) under FDA review with a PDUFA target action date of May 31, 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(9.31) million | $(3.85) million |
| Operating Loss | $(7.92) million | $(3.71) million |
| Cash and Cash Equivalents (End of Period) | $25.89 million | $9.52 million |
| Net Cash Used in Operating Activities | $(6.91) million | $(4.61) million |
| Net Cash Provided by Financing Activities | $21.91 million | $1.92 million |
| Total Debt (Current + Long-Term) | $6.15 million | $7.45 million |
| Accumulated Deficit | $(141.69) million | $(113.78) million |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased 141.7% to $9.31 million, driven primarily by a 287% increase in General and Administrative (G&A) expenses and a significant loss on debt extinguishment.
- G&A Expenses: Rose from $1.48 million to $5.74 million. This was largely due to $3.53 million in pre-commercialization costs (marketing, market access, pricing) in preparation for a potential CTx-1301 launch.
- R&D Expenses: Remained relatively flat at $2.18 million (down 1.8%), as decreased clinical operations costs were offset by increased drug manufacturing and regulatory costs related to the NDA review.
- Debt Restructuring: The Company extinguished its 2024 Note with Streeterville Capital by exchanging $2.31 million of principal, fees, and interest for 460,122 shares of common stock, recording a $336,781 loss on debt extinguishment.
- Capital Raise: Financing activities surged with $21.91 million in net proceeds from a Private Placement ($12.0 million), the 2025 Lincoln Park Purchase Agreement ($9.0 million), and ATM offerings.
Guidance, Outlook, and Risks
- Regulatory Milestone: The FDA has requested additional Chemistry, Manufacturing, and Controls (CMC) information for CTx-1301. Approval is targeted for May 31, 2026, but there is no assurance of approval or timing.
- Liquidity and Going Concern: Management states that cash of $25.9 million is sufficient to fund operations into early 2027. However, the filing includes a "substantial doubt" disclosure regarding the Company's ability to continue as a going concern within one year if additional capital is not raised.
- Commercialization: The Company has engaged Indegene for commercialization services and IQVIA for field-based sales support, pending FDA approval.
- Debt Covenants: The 2025 Note with Avondale Capital includes redemption requirements starting May 7, 2026, and restrictions on issuing new equity unless proceeds are used to pay down the note upon an event of default.
- Accounting Correction: The Company corrected a prior period error regarding the classification of derivative instruments related to the Lincoln Park Purchase Agreement, which increased the reported net loss for Q1 2025.
Investor Verification Checklist
- FDA Status: Verify the status of the FDA's CMC information request for CTx-1301 and the likelihood of meeting the May 31, 2026 PDUFA date.
- Cash Runway: Confirm the burn rate and the sufficiency of the $25.9 million cash balance to reach commercialization or secure further funding before early 2027.
- Debt Obligations: Review the terms of the 2025 Avondale Note, specifically the monthly redemption schedule starting May 2026 and potential default triggers.
- Dilution: Assess the impact of recent equity issuances (Private Placement, ATM, Lincoln Park) and outstanding warrants (2.62 million) on shareholder dilution.
- Commercial Readiness: Evaluate the costs associated with the $3.5 million in pre-commercialization expenses and the readiness of the sales force and manufacturing partners.